Clinical Trials for Uterine Cancer

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with incurable locally advanced, recurrent, or metastatic solid tumors and ECOG performance status 0–1 receive IV RO7502175 (enzelkitug) alone or with atezolizumab or pembrolizumab. RO7502175 is an investigational afucosylated anti-CCR8 antibody designed to deplete tumor-associated regulatory T cells.

ClinicalTrials.gov ID: NCT05581004

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors and ECOG performance status 0–1 receive IACS-6274, an investigational glutaminase-1 inhibitor, alone or with bevacizumab plus weekly paclitaxel or with the AKT inhibitor capivasertib. Combination cohorts focus on platinum-resistant ovarian cancer, KEAP1/NFE2L2-mutant non-small cell lung cancer, or low-ASNS high-grade serous ovarian cancer.

ClinicalTrials.gov ID: NCT05039801

An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced solid tumors lacking standard treatment options may receive intravenous ADU-1805 alone or with pembrolizumab; combination expansion cohorts enroll selected patients with microsatellite-stable colorectal or endometrial cancer, renal cell carcinoma, or non-small cell lung cancer. ADU-1805 is an investigational anti-SIRPα antibody designed to block the SIRPα–CD47 signal and promote macrophage engulfment of tumor cells.

ClinicalTrials.gov ID: NCT05856981